Cargando…
ZFN-mediated in vivo gene editing in hepatocytes leads to supraphysiologic α-Gal A activity and effective substrate reduction in Fabry mice
Fabry disease, a lysosomal storage disorder resulting from the deficient activity of α-galactosidase A (α-Gal A), is characterized by cardiac, renal, and/or cerebrovascular disease due to progressive accumulation of the enzyme’s substrates, globotriaosylceramide (Gb3) and globotriaosylsphingosine (L...
Autores principales: | Pagant, Silvere, Huston, Marshall W., Moreira, Luciana, Gan, Lin, St Martin, Susan, Sproul, Scott, Holmes, Michael C., Meyer, Kathleen, Wechsler, Thomas, Desnick, Robert J., Yasuda, Makiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572137/ https://www.ncbi.nlm.nih.gov/pubmed/33775910 http://dx.doi.org/10.1016/j.ymthe.2021.03.018 |
Ejemplares similares
-
AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction
por: Yasuda, Makiko, et al.
Publicado: (2020) -
ZFN-Mediated In Vivo Genome Editing Corrects Murine Hurler Syndrome
por: Ou, Li, et al.
Publicado: (2019) -
Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing
por: Laoharawee, Kanut, et al.
Publicado: (2018) -
Expanded activity of dimer nucleases by combining ZFN and TALEN for genome editing
por: Yan, Wei, et al.
Publicado: (2013) -
Effect of ZFN-edited myostatin loss-of-function mutation on gut microbiota in Meishan pigs
por: Cui, Wen-Tao, et al.
Publicado: (2019)